Hepatitis C Therapy

Hepatitis C virus replication is inhibited by cyclosporin DEBIO-025 in vitro

Published in Hepatitis Weekly, May 22nd, 2006

According to recent research from Belgium, hepatitis C virus (HCV) replication is inhibited by cyclosporin DEBIO-025 in vitro.

"Cyclosporin A (CsA) inhibits the in vitro replication of HCV subgenomic replicons. We here report on the potent anti-HCV activity of the non-immunosuppressive cyclosporin DEBIO-025," wrote J. Paeshuyse and colleagues, Rega Institute.

"The 50% effective concentration for inhibition of HCV subgenomic replicon replication in Hub 5-2 cells (luciferase assay) by DEBIO-025 was 0.27±0.03 mcg/mL and for CsA 2.8±0.4 mcg/mL. The concentration that reduced the growth of exponentially proliferating Hub 5-2 cells by 50% was...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2006-05-22)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry